Biotron Limited (ASX:BIT)

Australia flag Australia · Delayed Price · Currency is AUD
0.0030
0.00 (0.00%)
Sep 25, 2025, 9:59 AM AEST
Market Cap4.65M
Revenue (ttm)1.81M
Net Income (ttm)-318.57K
Shares Out1.33B
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume50,000
Average Volume1,507,569
Open0.0030
Previous Close0.0030
Day's Range0.0030 - 0.0030
52-Week Range0.0020 - 0.0210
Beta-0.69
RSI48.56
Earnings DateAug 27, 2025

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 3
Stock Exchange Australian Securities Exchange
Ticker Symbol BIT
Full Company Profile

Financial Performance

In 2025, Biotron's revenue was 1.81 million, an increase of 10.24% compared to the previous year's 1.65 million. Losses were -318,572, -90.73% less than in 2024.

Financial Statements

News

There is no news available yet.